Eckert & Ziegler AG
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000BSBF36
EUZ
Eckert & Ziegler AG
GICS: 35101010
·
Sector: Medical equipment
·
Sub-Sector: -
NAME
Eckert & Ziegler AG
ISIN
DE0005659700
TICKER
EUZ
MIC
XETR
REUTERS
EUZG.DE
BLOOMBERG
EUZ GR
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Fri, 22.11.2024
Eckert & Ziegler raises its forecast for the current financial year once again.Forecast for 2024:
Sales of around EUR 290 million (raised)
EBIT before special items of around EUR 60 million (raised)
Berlin, 22 November 2024 Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) is once again raising its annual forecast for the current financial ...
Thu, 14.11.2024
Berlin, November 14, 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 m...
Wed, 13.11.2024
Berlin, 13 November 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a collaboration and licence agreement with the Australian-headquartered Telix Pharmaceuticals Limited (Telix) for the use of EZAG’s cyclotron-based technology to produce Ac-225. The contract entitles Eckert & Ziegler to milestone payments from Telix total...
Tue, 15.10.2024
3rd quarter of 2024:
Sales of EUR 70.1 million (previous year: EUR 65.9 million)
EBIT before special items of EUR 15.5 million (previous year: EUR 15.1 million)
Net income of EUR 5.3 million (previous year: EUR 9.4 million)
First 9 months of 2024:
Sales of EUR 215.5 million (previous year: EUR 183.9 million)
EBIT before special items of EUR ...
Tue, 08.10.2024
Berlin, Germany and Sydney, Australia - 08. October 2024 - Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid tumors, today announced a new global clinical supply agreement. Eckert & Ziegler will provide its...
Wed, 02.10.2024
Berlin, 2 October 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) announces that the spin-off resolution approved at the Annual General Meeting on 26 June 2024 was entered in the commercial register of the Charlottenburg (Berlin) District Court today. With the entry in the commercial register of Eckert & Ziegler SE, the spin-off of Pe...
Tue, 20.08.2024
Berlin, 20.08.2024. In the presence of the Saxon State Ministers Martin Dulig and Thomas Schmidt as well as the Mayor of Dresden Dirk Hilbert, the medical technology company Eckert & Ziegler today inaugurated its new 1,700 square meter facilities in Dresden with around 200 guests. The Dresden-Rossendorf site produces and delivers high-tech syst...
Tue, 13.08.2024
Berlin, August 13, 2024 - Eckert & Ziegler and Telix Pharmaceuticals Limited (Telix) today announced the signing of a significant multi-year agreement under which Eckert & Ziegler will serve as the European contract manufacturing organization (CMO) for Telix's ProstACT GLOBAL Phase III study. The contract covers the supply of the entire Eur...
Fri, 09.08.2024
2nd Quarter 2024:
Sales: € 77.8 Mio. million (PY: € 60.1 million)
EBIT before special items: € 17.5 million (PY: € 12.0 million)
Net income: € 9.5 million (PY: € 6.2 million)
1st Half Year 2024:
Sales: € 145,4 million (PY: € 118.0 million)
EBIT before special items: € 32.5 million (PY: € 22.6 million)
Net income: € 18.0 million (PY: € 10.9 mi...
Mon, 05.08.2024
August 5, 2024 - Berlin - Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) has received approval from the European Commission (EC) for its Ge-68/Ga-68 radionuclide generator GalliaPharm®. The generator was first launched in 2014 and is today approved in 17 European countries and many other key international markets. With the EC approval...
Information on product placements
